Afferent Steps Boldly Into Neurotherapeutic Arena With New Shoe Insole
This article was originally published in The Gray Sheet
Afferent expects to launch a non-invasive shoe insole technology for the palliative treatment of diabetic foot neuropathy in the second half of 2006
You may also be interested in...
$750,000 NIH grant will be used to advance neurostimulation device development for stroke patients. The Providence, R.I. firm owns the patents for the technology, which is used to stimulate peripheral structures of the nervous system to alter brain function and restore motor control. Approximately 4.5 mil. Americans suffer from sensory effects due to brain function loss, according to CEO Jason Harry, PhD. The device, consisting of a power generator and surface electrodes, could reach the U.S. market by late 2007. Other possible indications include diabetic peripheral neuropathy and improving sensory function in the elderly...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.